Cholera toxin B subunit pentamer reassembled from Escherichia coli inclusion bodies for use in vaccination.
Cholera toxin B subunit pentamer reassembled from Escherichia coli inclusion bodies for use in vaccination.
复制标题
由大肠杆菌包涵体重组而成的霍乱毒素 B 亚基五聚体,用于疫苗接种。
DOI:
10.1016/j.vaccine.2016.01.034
复制
发表时间:
2016
期刊:
影响因子:
5.5
通讯作者:
Arakawa T
中科院分区:
文献类型:
--
作者:
Tamaki Y;Harakuni T;Yamaguchi R;Miyata T;Arakawa T
The cholera toxin B subunit (CTB) is secreted in its pentameric form fromEscherichia coliif its leader peptide is replaced with one ofE. coliorigin. However, the secretion of the pentamer is generally severely impaired when the molecule is mutated or fused to a foreign peptide. Therefore, we attempted to regenerate pentameric CTB from the inclusion bodies (IBs) ofE. coli. Stepwise dialysis of the IBs solubilized in guanidine hydrochloride predominantly generated soluble high-molecular-mass (HMM) aggregates and only a small fraction of pentamer. Three methods to reassemble homogeneous pentameric molecules were evaluated: (i) using a pentameric coiled-coil fusion partner, expecting it to function as an assembly core; (ii) optimizing the protein concentration during refolding; and (iii) eliminating contaminants before refolding. Coiled-coil fusion had some effect, but substantial amounts of HMM aggregates were still generated. Varying the protein concentration from 0.05 mg/mL to 5 mg/mL had almost no effect. In contrast, eliminating the contaminants before refolding had a robust effect, and only the pentamer was regenerated, with no detectable HMM aggregates. Surprisingly, the protein concentration at refolding was up to 5 mg/mL when the contaminants were removed, with no adverse effects on refolding. The regenerated pentamer was indistinguishable in its biochemical and immunological characteristics from CTB secreted fromE. colior choleragenoid fromVibrio cholerae. This study provides a simple but very efficient strategy for pentamerizing CTB with a highly homogeneous molecular conformation, with which it may be feasible to engineer CTB derivatives and CTB fusion antigens.